Kinnevik
VC Fund
Stockholm, Sweden
Kinnevik is an industry-focused investment company with an entrepreneurial spirit. Its purpose is to build digital consumer businesses that provide more and better choices. The company does this by working in partnership with talented founders and management teams to create, invest in, and lead fast-growing businesses in developed and emergingmarkets.Kinnevik believes in delivering both shareholder and social value by building well-governed companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor, and von Horn families. Kinnevik's shares are listed on Nasdaq Stockholm's list for large-cap companies under the ticker codes KINV A and KINV B.
- Total investments:
- 188
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Kinnevik invests in
Stages Kinnevik invests in
Countries Kinnevik invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 16 contacts → | |||
Round size
- Series A
- $2M–$91M
- Series B
- $23M–$120M
- Series C
- $38M–$200M
Investment Focus
Industry
- E-Commerce 25 (13%)
- Health Care 13 (7%)
- Financial Services 12 (6%)
- FinTech 10 (5%)
- Internet 10 (5%)
Stage
- Series B 28 (15%)
- Series C 21 (11%)
- Series A 20 (11%)
- Series D 15 (8%)
- Venture - Series Unknown 13 (7%)
Country
- United States 22 (12%)
- Sweden 12 (6%)
- Germany 12 (6%)
- United Kingdom 9 (5%)
- Denmark 5 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Bernstrom
Senior Investment Director
|
Senior Investment Director | Total investments: 13 | Find email | |
Magnus Jakobson
Corporate Finance Director
|
Corporate Finance Director | Total investments: 2 | Find email | |
Ola Nordbye
Venture & Growth Investor
|
Venture & Growth Investor | Total investments: 2 | Find email | |
Anders Strandberg
Legal Professional
|
Legal Professional | Total investments: 0 | Find email | |
Christian Scherrer
Investment Manager
|
Investment Manager | Total investments: 12 | Find email | |
| See all 16 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $311M / Series E / Sep 23, 2026 | ||
| Tandem Health develops AI tools that support clinical documentation, coding, decision support, and follow-up across healthcare workflows. Its AI Medical Scribe captures conversations during patient visits and converts relevant information into structured clinical notes, referrals, summaries, and other documents for review. The platform alsoprovides suggested diagnosis and procedure codes and allows clinicians to edit documentation through voice commands. Tandem Health integrates with medical record, dental, pharmacy, and care-management systems, enabling approved notes and related documents to transfer directly into existing records. Its solutions support healthcare professionals across medical, nursing, physiotherapy, dental, mental health, social care, and veterinary settings. | $100M / Series B / Sep 14, 2026 | ||
| Co:Helm builds AI assistants that utilizes ChatGPT built with healthcare operations as the core focus. Co:Helm's interopability engine allows users to seamlessly integrate with any EHR or EMR system in less than a day. Co:Helm automates Prior Authorization for Utilization Management teams using AI resulting in a massive 90% time saving. | $40M / Series B / Feb 12, 2026 | ||
| Mews is a cloud-native hospitality platform that provides property management, guest services, payments, and operations tools in a unified system. It helps hotels, hostels, and accommodation groups automate reservations, check-in/out, rate and inventory management, housekeeping, and embedded payment processing through a single dashboard. Theplatform also supports integrations with a wide range of third-party applications and open APIs to extend functionality and adapt to specific business needs. Mews emphasizes an intuitive interface and automation to reduce manual tasks and enable staff to focus on guest interactions and operational workflows. The system includes tools for revenue management, point of sale, event management, and analytics for decision support.Mews serves over 5000 properties across more than 85 countries in all five continents, and works with a huge number of hospitality tech companies to provide hoteliers with an unbeatable platform – no other PMS offers as many integrations. At the 2024 HotelTechAwards, Mews was voted Best PMS by industry peers. | $300M / Series D / Jan 22, 2026 | ||
| Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | $233.7M / Series D / Jan 22, 2026 | ||
| Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | Secondary Market / Jan 22, 2026 | ||
| Encube Technologies operates as a visual collaboration platform where hardware teams come together to explore designs, share insights and shape ideas. | $23M / Series A / Oct 16, 2025 | ||
| Nory is the all-knowing restaurant management system that learns the behind the scenes of your business. Helping you forecast sales, plan labour & optimise your inventory. | $36.7M / Series B / Sep 15, 2025 | ||
| Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $150M / Series D / Sep 04, 2025 | ||
| Aira operates as a clean energy-tech company. | $174.3M / Venture - Series Unknown / Aug 11, 2025 | ||
| See all 188 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kinnevik invest in?
Kinnevik invests primarily in E-Commerce, Health Care and Financial Services startups, most often at Series B and Series C stage. Most of the 188 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Kinnevik's check size?
Kinnevik typically joins rounds of $2M–$91M at Series A, $23M–$120M at Series B and $38M–$200M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kinnevik participates in.
How do I contact Kinnevik?
Public channels for Kinnevik include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kinnevik?
The team at Kinnevik includes Andreas Bernstrom (Senior Investment Director), Magnus Jakobson (Corporate Finance Director) and Ola Nordbye (Venture & Growth Investor), among 16 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
